Bill C-17 (Historical)

Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)

An Act to amend the Food and Drugs Act

This bill was last introduced in the 41st Parliament, 2nd Session, which ended in August 2015.

Sponsor

Rona Ambrose  Conservative

Status

This bill has received Royal Assent and is now law.

Summary

This is from the published bill. The Library of Parliament often publishes better independent summaries.

This enactment amends the Food and Drugs Act regarding therapeutic products in order to improve safety by introducing measures to, among other things,
(a) strengthen safety oversight of therapeutic products throughout their life cycle;
(b) improve reporting by certain health care institutions of serious adverse drug reactions and medical device incidents that involve therapeutic products; and
(c) promote greater confidence in the oversight of therapeutic products by increasing transparency.

Elsewhere

All sorts of information on this bill is available at LEGISinfo, an excellent resource from the Library of Parliament. You can also read the full text of the bill.

Health Committee, on June 5, 2014

  • Anne Lamar, Acting Assistant Deputy Minister, Health Products and Food Branch, Department of Health
  • David Lee, Director, Office of Legislative and Regulatory Modernization, Policy, Planning and International Affairs Directorate, Health Products and Food Branch, Department of Health
  • Supriya Sharma, Acting Associate Assistant Deputy Minister, Health Products and Food Branch, Department of Health

Health Committee, on June 10, 2014

  • Janice E. Graham, Professor of Pediatrics, Faculty of Medicine, Dalhousie University, As an Individual
  • Joel Lexchin, Professor, School of Health Policy and Management, York University, As an Individual
  • Elaine Gibson, Associate Professor, Health Law Institute, Dalhousie Schulich School of Law, As an Individual
  • Matthew Herder, Assistant Professor, Faculties of Medicine and Law, Health Law Institute, Dalhousie University, As an Individual
  • Sylvia Hyland, Vice President and Chief Operating Officer, Institute for Safe Medication Practices Canada

Health Committee, on June 12, 2014

  • Jim Keon, President, Canadian Generic Pharmaceutical Association
  • Walter Robinson, Vice-President, Government Affairs, Canada's Research-Based Pharmaceutical Companies (Rx & D)
  • Nancy Abbey, Executive Director, Reuse of Single-Use Devices Task Force, MEDEC - Canada’s Medical Technology Companies
  • Keith McIntosh, Senior Director, Scientific and Regulatory Affairs, Canada's Research-Based Pharmaceutical Companies (Rx & D)
  • Linda Wilhelm, Chair, Operations Committee, Best Medicines Coalition
  • Jeff Morrison, Director, Government Relations and Public Affairs, Canadian Pharmacists Association
  • Helen Long, President, Canadian Health Food Association
  • Barry Power, Pharmacy Consultant, Canadian Pharmacists Association
  • David Lee, Director, Office of Legislative and Regulatory Modernization, Policy, Planning and International Affairs Directorate, Health Products and Food Branch, Department of Health
  • Supriya Sharma, Acting Associate Assistant Deputy Minister, Health Products and Food Branch, Department of Health
  • Philippe Méla, Procedural Clerk
  • David Edwards, Senior Counsel, Legal Services Unit--Health Canada, Department of Justice